Exelixis, Inc. (NASDAQ:EXEL) Stake Boosted by Neo Ivy Capital Management

Neo Ivy Capital Management boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 427.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 53,892 shares of the biotechnology company's stock after purchasing an additional 43,682 shares during the period. Neo Ivy Capital Management's holdings in Exelixis were worth $1,794,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. JT Stratford LLC acquired a new stake in Exelixis during the 4th quarter valued at approximately $288,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Exelixis by 4.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company's stock valued at $28,117,000 after purchasing an additional 33,804 shares during the period. Voloridge Investment Management LLC acquired a new position in shares of Exelixis in the 4th quarter valued at $30,321,000. Worldquant Millennium Advisors LLC acquired a new position in shares of Exelixis in the 4th quarter valued at $247,000. Finally, Vident Advisory LLC lifted its stake in shares of Exelixis by 31.0% in the 4th quarter. Vident Advisory LLC now owns 155,874 shares of the biotechnology company's stock valued at $5,191,000 after purchasing an additional 36,850 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on EXEL shares. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Piper Sandler boosted their price target on shares of Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Citigroup boosted their price target on shares of Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Finally, Barclays increased their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and an average price target of $38.94.

Insider Activity

In related news, Director Tomas J. Heyman sold 4,544 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total transaction of $201,253.76. Following the completion of the sale, the director now owns 32,470 shares of the company's stock, valued at approximately $1,438,096.30. This represents a 12.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. This trade represents a 2.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 459,276 shares of company stock valued at $20,945,859 in the last 90 days. 2.82% of the stock is currently owned by insiders.

Exelixis Price Performance

NASDAQ:EXEL traded up $0.70 on Tuesday, reaching $43.09. The stock had a trading volume of 3,409,006 shares, compared to its average volume of 2,306,836. The company has a market cap of $11.75 billion, a price-to-earnings ratio of 24.34, a P/E/G ratio of 1.13 and a beta of 0.25. The firm's fifty day moving average is $38.02 and its two-hundred day moving average is $36.19. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $48.85.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.